DelistingJun 12, 2026, 05:11 PM
Genprex Faces Nasdaq Delisting; Plans Hearing & Reverse Split
AI Summary
Genprex, Inc. received a letter from Nasdaq on June 10, 2026, indicating its common stock is subject to delisting due to non-compliance with the $1.00 minimum bid price requirement over the past 30 consecutive business days. The company is ineligible for a compliance period because it previously effected a reverse stock split on October 21, 2025. Genprex intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay the delisting action, and plans to take definitive steps, including potentially another reverse stock split, to regain compliance.
Key Highlights
- Genprex received a Nasdaq delisting notice on June 10, 2026.
- Non-compliance with Nasdaq's $1.00 minimum bid price requirement for 30 consecutive days.
- Ineligible for compliance period due to a reverse stock split on October 21, 2025.
- Company intends to timely request a hearing with a Nasdaq Hearings Panel.
- The hearing request will automatically stay any suspension or delisting action.
- Genprex may consider another reverse stock split to regain compliance.
- Compliance requires a $1.00 bid price for at least 10 consecutive business days.
Price Impact
More from GNPX